SOURCE: CytoSorbents Corporation

CytoSorbents Corporation

April 19, 2012 08:00 ET

CytoSorbents Receives European Trademark for CytoSorb®

MONMOUTH JUNCTION, NJ--(Marketwire - Apr 19, 2012) - CytoSorbents Corporation (OTCBB: CTSO), a critical care-focused company using blood purification to treat life-threatening illnesses, announced that it has received the registered trademark for CytoSorb® in the European Union. CytoSorb® is also a registered trademark in the United States.

Dr. Phillip Chan, Chief Executive Officer, stated, "This represents another important step in the branding and commercialization of CytoSorb® in Europe. We believe that CytoSorb® is a memorable name that easily invokes its use as a 'cytokine adsorber' and is compatible with the broad approval in the European Union to be used in any clinical situation where cytokines are elevated. The goal of CytoSorb® is to quell the massive inflammation caused by 'cytokine storm,' limit the systemic inflammatory response syndrome (SIRS), and prevent or mitigate multi-organ failure, the leading cause of death in the intensive care unit today. No other class of therapy has the potential to impact the outcome of so many life-threatening illnesses, such as sepsis, burn injury, trauma, acute respiratory distress syndrome, and pancreatitis, the way CytoSorb® potentially can."

About CytoSorbents and CytoSorb®

CytoSorbents Corporation is a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption that standard blood purification cannot. In March 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval under the CE Mark as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) for use in clinical situations where cytokines are elevated. CytoSorb® has demonstrated statistically significant reductions in mortality in septic patients at high risk of death and is now available for sale in Germany for the treatment of critical care illnesses under a controlled market release, with a planned broad product launch in Germany anticipated for the first half of 2012. CytoSorb® will be made available in other E.U. countries, assuming adequate and timely funding, and continued positive results from our clinical studies. CytoSorb® and other polymers under development have been designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy drugs during treatment of cancer with high dose regional chemotherapy, drug detoxification, and others. Additional information is available for download on the Company's website:
http://www.cytosorbents.com.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc. believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and additional CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate and timely financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on March 30, 2012, which is available at http://www.sec.gov.

Contact Information

  • Contact:
    CytoSorbents Corporation
    David Lamadrid
    Chief Financial Officer
    (732) 329-8885 ext. 816
    DavidL@cytosorbents.com